Whereas in pediatric ALL, the clinical significance of CNA has been well recognized and incorporated, e.g., into the integrated risk scoring system widely used in clinical trials, with the particular role of IKZF1 deletions coexisting with other concomitant CNAs. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.